Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab plus Neoadjuvant Chemotherapy in Selected Sarcomas
NCT04968106Phase 2Active, not recruiting
- Sponsor
- Institut Bergonié
- Start
- Dec 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of retifanlimab in soft tissue sarcoma (STS) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Assessment of the antitumor activity at 5 months. Started Dec 2022; status: active, not recruiting.
02
Drugs
retifanlimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04968106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968106.